VK Gadi, MD, PhD

Articles

Establishing the Paradigm of HER2-Low Breast Cancer

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer

August 1st 2022

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

HER2+ mBC: Practical Selection and Sequencing of Therapy

August 1st 2022

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer

July 25th 2022

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

HER2+ Metastatic Breast Cancer: Safety Data With T-DXd

July 25th 2022

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Overview of Treatment Options in HER2+ Metastatic Breast Cancer

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Early-Stage HER2+ Breast Cancer: Novel Perioperative Treatment Strategies

July 11th 2022

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.

Establishing the Role of Neratinib Therapy in Early-Stage HER2+ Breast Cancer

July 11th 2022

Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.

Updates in the Treatment of HER2+ mBC from ASCO 2022

July 8th 2022

A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.

Role of Multidisciplinary Team in the Management of Patients with HER2+ BC and CNS Metastases

July 8th 2022

Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.

Early Stage HER2+ Breast Cancer: Optimizing Use of T-DM1

July 4th 2022

A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.

Subcutaneous HP Therapy in Early-Stage HER2+ Breast Cancer

July 4th 2022

Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

July 1st 2022

An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

July 1st 2022

Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

March 10th 2022

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Treatment Options for HER2+, ER+ Metastatic Breast Cancer

March 2nd 2022

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

March 2nd 2022

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.